The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy

Yu-Feng LiDepartment of Hematology, No. 1 Hospital of Huaian affiliated to Nanjing Medical University, Huaian, Jiangsu, ChinaCorrespondence[email protected]

Xiaolin LiuDepartment of Hematology, No. 1 Hospital of Huaian affiliated to Nanjing Medical University, Huaian, Jiangsu, China

Ding-Shen LiuDepartment of Hematology, No. 1 Hospital of Huaian affiliated to Nanjing Medical University, Huaian, Jiangsu, China

Ban-He DinDepartment of Hematology, No. 1 Hospital of Huaian affiliated to Nanjing Medical University, Huaian, Jiangsu, China

Jian-Bin ZhuDepartment of Hematology, No. 1 Hospital of Huaian affiliated to Nanjing Medical University, Huaian, Jiangsu, China

References

Donato NJ, Wu JY, Stapley J, et al Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672–677.
PubMed Web of Science ®Google Scholar
Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16: 122–131.
PubMed Web of Science ®Google Scholar
Marin D, Kaeda JS, Andreasson C, et al Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850–1855.
PubMed Web of Science ®Google Scholar
Quintás-Cardama A, Kantarjian H, Garcia-Manero G, et al Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248–255.
PubMed Web of Science ®Google Scholar
Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006;66:10959–10966.
PubMed Web of Science ®Google Scholar
Baccarani M, Saglio G, Goldman J. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
PubMed Web of Science ®Google Scholar
Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;93:161–169.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date